Telitacicept

Phase 3Protein / enzyme

VVor Biopharma

Telitacicept is one of 256 biologic programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

255

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusTerminated

Connective Tissue DiseaseRecruiting

Nephrotic SyndromeRecruiting

Rheumatoid ArthritisRecruiting

Myasthenia GravisNot yet recruiting

Systemic SclerosisRecruiting

ANCA-Associated VasculitisRecruiting

Iga NephropathyActive, not recruiting

Lupus NephritisRecruiting

Membranous NephropathyNot yet recruiting

Systemic Lupus ErythematosusPhase 3

Terminated

Connective Tissue DiseasePhase 2

Recruiting

Nephrotic SyndromePhase 3

Recruiting

Rheumatoid ArthritisPhase 2

Recruiting

Myasthenia GravisPhase 3

Not yet recruiting

Systemic SclerosisPhase 3

Recruiting

ANCA-Associated VasculitisPhase 3

Recruiting

Iga NephropathyPhase 3

Active, not recruiting

Lupus NephritisPhase 2

Recruiting

Membranous NephropathyPhase 2

Not yet recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

228 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Lutathera

Novartis

Phase 3

1 2

Telitacicept

VVor Biopharma

Phase 3

4 3

Mitomycin C

GGynecologic Oncology Group

Phase 3

2 4

S1,

CChinese Academy of Medical Sciences

Phase 3

1 5

Romiplostim N01

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 6

HSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

3 7

Imlifidase

HHansa Biopharma AB

Phase 3

2 8

AVTX-803

AAUG Therapeutics

Phase 3

1 9

IBI302

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

1 10

Rengalin

MMateria Medica Holding

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Myasthenia Gravis

NCT06723548

N/ARecruiting

Efficacy and Safety

NCT06654596

Post-ApprovalRecruiting

ANCA-Associated Vasculitis

NCT05962840

Post-ApprovalRecruiting

ANCA-Associated Vasculitis

NCT05965284

Q1 2027

Phase 3Recruiting

Myasthenia Gravis

NCT07249632

Phase 2/3Not yet recruiting

Inflammatory Myopathies

NCT07355257

Clinical

Trials by Indication[1]

Telitacicept6 trials

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Unknown status·FFen Li·Phase 4·NCT05666336·30 enrolled

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Telitacicept for the Treatment of Refractory RA

Not yet recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT07008196·30 enrolled

Show 3 more trials

Telitacicept in Primary APS Patients

Terminated·PPeking Union Medical College Hospital·Phase 2·NCT05078710·20 enrolled

Telitacicept for PGNMID: A Single-Arm Study

Active, not recruiting·PPeking University First Hospital·Phase 2·NCT07111338·10 enrolled

Immune Cell Subsets in SLE Patients Treated with Telitacicept

Active, not recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT06677801·50 enrolled

IgA Nephropathy5 trials

Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis

Not yet recruiting·GGuixia Ding·Phase 3·NCT07052981·124 enrolled

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

Active, not recruiting·RRemeGen Co., Ltd.·Phase 3·NCT05799287·318 enrolled

Study of Telitacicept in Patients With Refractory IgA Nephropathy

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT05596708·40 enrolled

Show 2 more trials

To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy

Active, not recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 3·NCT07098897·150 enrolled

A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy

Terminated·RRemeGen Co., Ltd.·Phase 2·NCT04905212·15 enrolled

Systemic Lupus Erythematosus5 trials

A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus

Completed·RRemeGen Co., Ltd.·Phase 1·NCT05687526·16 enrolled

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)

Terminated·VVor Biopharma·Phase 3·NCT05306574·91 enrolled

Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus

Completed·RRemeGen Co., Ltd.·Phase 1·NCT05247203·92 enrolled

Show 2 more trials

Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus

Recruiting·LLiu Tian·Phase 3·NCT05339217·60 enrolled

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Withdrawn·VVor Biopharma·Phase 3·NCT06456567

Efficacy and Safety4 trials

Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients

Recruiting·RRenJi Hospital·N/A·NCT06394063·176 enrolled

Efficacy and Safety of Telitacicept in Early SLE

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT05899907·180 enrolled

Efficacy and Safety of Telitacicept in IgAN

Recruiting·RRuijin Hospital·N/A·NCT06654596·118 enrolled

Show 1 more trial

The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)

Active, not recruiting·RRenmin Hospital of Wuhan University·Phase 1/2·NCT06656962·15 enrolled

Myasthenia Gravis4 trials

A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis

Not yet recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·N/A·NCT07298928·30 enrolled

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06723548·30 enrolled

Study of Telitacicept in Generalized Myasthenia Gravis

Completed·RRemeGen Co., Ltd.·Phase 3·NCT05737160·114 enrolled

Show 1 more trial

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

Recruiting·RRemeGen Co., Ltd.·Phase 3·NCT07249632·120 enrolled

16 more indications

Lupus Nephritis3 trials

The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School··NCT05588830·60 enrolled

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Recruiting·NNanjing University School of Medicine·Phase 2·NCT07340463·50 enrolled

A Study of Telitacicept in Lupus Nephritis

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT05680480·120 enrolled

Systemic Sclerosis2 trials

Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06375005·38 enrolled

The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis

Recruiting·PPeking University Third Hospital·Phase 4·NCT06546540·20 enrolled

ANCA-Associated Vasculitis2 trials

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05962840·40 enrolled

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

Recruiting·CChinese SLE Treatment And Research Group·Phase 4·NCT05965284·40 enrolled

Nephrotic Syndrome1 trial

Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 3·NCT06125405·20 enrolled

Lupus Erythematosus1 trial

Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia

Unknown status·GGuanmin Gao·Phase 2·NCT05929248·64 enrolled

Membranous Nephropathy1 trial

The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy

Not yet recruiting·RRenmin Hospital of Wuhan University·Phase 2·NCT06614985·172 enrolled

Connective Tissue Disease1 trial

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Recruiting·—·Phase 2·NCT05998759·296 enrolled

Primary Sjogren's Syndrome1 trial

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Completed·RRemeGen Co., Ltd.·Phase 3·NCT05673993·381 enrolled

Inflammatory Myopathies1 trial

TELITACICEPT IN INFLAMMATORY MYOPATHIES(TELITACICEPT-IM)

Not yet recruiting·ZZhongming Qiu·Phase 2/3·NCT07355257·30 enrolled

Antibody-mediated Rejection1 trial

STABILIZE Trial: Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial

Active, not recruiting·FFirst Affiliated Hospital, Sun Yat-Sen University·Phase 2·NCT07902609·20 enrolled

IgA Nephropathy (IgAN)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of IBI3034 Following Single Ascending Dose in Healthy Adults and Multiple Ascending Doses in Participants With Primary IgA Nephropathy

Not yet recruiting· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT07886476·100 enrolled

Primary1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren's Disease

Recruiting·VVor Biopharma·Phase 3·NCT07404865·250 enrolled

Generalized Myasthenia Gravis1 trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis

Active, not recruiting·VVor Biopharma·Phase 3·NCT06456580·191 enrolled

Sjögren's Disease1 trial

A Prospective Cohort Study of Telitacicept Versus Conventional Immunosuppressive Agents in Primary Sjögren's Disease With Interstitial Lung Disease

Recruiting·PPeking University People's Hospital··NCT07843381·60 enrolled

Immunoglobulin A Nephropathy (IgAN)1 trial

A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease

Recruiting·AADARx Pharmaceuticals, Inc.·Phase 2·NCT07522099·30 enrolled

Rheumatoid Arthritis1 trial

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis: A Multicenter, Open-Label, Randomized Controlled Study

Recruiting·PPeking University People's Hospital·Phase 2·NCT07796516·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 44 trial records for Telitacicept. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telitacicept compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telitacicept. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vor Biopharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: VVor Biopharma

Telitacicept

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Telitacicept6 trials

IgA Nephropathy5 trials

Systemic Lupus Erythematosus5 trials

Efficacy and Safety4 trials

Myasthenia Gravis4 trials

Lupus Nephritis3 trials

Systemic Sclerosis2 trials

ANCA-Associated Vasculitis2 trials

Nephrotic Syndrome1 trial

Lupus Erythematosus1 trial

Membranous Nephropathy1 trial

Connective Tissue Disease1 trial

Primary Sjogren's Syndrome1 trial

Inflammatory Myopathies1 trial

Antibody-mediated Rejection1 trial

IgA Nephropathy (IgAN)1 trial

Primary1 trial

Generalized Myasthenia Gravis1 trial

Sjögren's Disease1 trial

Immunoglobulin A Nephropathy (IgAN)1 trial

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News